RecruitingNot ApplicableNCT07187063
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Sponsor
Lahey Clinic
Enrollment
56 participants
Start Date
Jan 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- AUA high-risk bladder cancer1
- Received induction BCG or gemcitabine/docetaxel
- Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)
Exclusion Criteria4
- High-risk NMIBC within 3 years
- Prior induction intravesical therapy
- Variant histology
- Concurrent upper tract disease
Interventions
DIAGNOSTIC_TESTUroAmp Test (Convergent Genomics, Inc.)
Non-invasive genomic urine test that can reliably detect, monitor, and predict the risk of urothelial cancer or its recurrence, potentially before signs and symptoms develop or become detectable by historical standards of care.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07187063
Related Trials
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
NCT072251276 locations
Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
NCT073397611 location
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
NCT063519043 locations
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
NCT0712241412 locations
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
NCT066967943 locations